Rani Therapeutics Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
RANI$0.56-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net loss | $(40,950) | $(56,584) |
| Other comprehensive loss | ||
| Net unrealized (loss) gain on marketable securities | (6) | 33 |
| Comprehensive loss | $(40,956) | $(56,551) |
| Comprehensive loss attributable to non-controlling interest | (11,279) | (26,550) |
| Comprehensive loss attributable to Rani Therapeutics Holdings, Inc. | $(29,677) | $(30,001) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.